CADL Candel Therapeutics Inc

Price (delayed)

$11.29

Market cap

$863.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$711.43M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0
Highlights
CADL's quick ratio has surged by 132% year-on-year but it is down by 43% since the previous quarter
Candel Therapeutics's equity has increased by 40% YoY but it has decreased by 9% QoQ
Candel Therapeutics's EPS has shrunk by 115% YoY and by 43% QoQ
The net income has dropped by 63% since the previous quarter

Key stats

What are the main financial stats of CADL

CADL stock price

How has the Candel Therapeutics stock price performed over time
Intraday
-4.73%
1 week
2.45%
1 month
-14.01%
1 year
113.42%
YTD
99.82%
QTD
9.61%

Financial performance

How have Candel Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$71.99M
Net income
-$88.53M
Gross margin
N/A
Net margin
N/A
The company's operating income has shrunk by 99% YoY and by 28% QoQ
The net income has dropped by 63% since the previous quarter

Price vs fundamentals

How does CADL's price correlate with its fundamentals

Growth

What is Candel Therapeutics's growth rate over time

Valuation

What is Candel Therapeutics stock price valuation
P/E
N/A
P/B
6.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Candel Therapeutics's EPS has shrunk by 115% YoY and by 43% QoQ
The P/B is 115% above the 5-year quarterly average of 3.2 and 53% above the last 4 quarters average of 4.5
Candel Therapeutics's equity has increased by 40% YoY but it has decreased by 9% QoQ

Efficiency

How efficient is Candel Therapeutics business performance
Candel Therapeutics's ROE has plunged by 118% YoY and by 48% from the previous quarter
CADL's ROA has plunged by 110% YoY and by 36% from the previous quarter
The company's return on invested capital fell by 12% QoQ

Dividends

What is CADL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CADL.

Financial health

How did Candel Therapeutics financials performed over time
The total assets is 154% greater than the total liabilities
CADL's quick ratio has surged by 132% year-on-year but it is down by 43% since the previous quarter
The current ratio has soared by 129% YoY but it has decreased by 43% from the previous quarter
Candel Therapeutics's debt is 61% lower than its equity
Candel Therapeutics's equity has increased by 40% YoY but it has decreased by 9% QoQ
CADL's debt to equity is up by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.